The feasibility to raise nonhuman primate antibodies against selected components of the human immune system was tested. The immunogens were whole cells (human T lymphocytes) or purified, recombinant human proteins (cytokines: TNF alpha or GM-CSF; soluble forms of cell surface antigens: sCD4 or sCD25). Significant immunizations, yielding functionally relevant antibodies, were readily achieved in rhesus monkeys, but, not surprisingly, may be less frequent in chimpanzees. The results suggest a general strategy for production of therapeutically useful MAB.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0684.1994.tb00286.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!